{'fraction_non_alphanumeric': 0.023504273504273504, 'fraction_numerical': 0.008547008547008548, 'mean_word_length': 4.8930817610062896, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preliminary Report on The Production of a Shiga-like Toxoid Fusion Protein as Associated with Novel FliC Vaccine

Shiga toxin (Stx) is an endotoxin produced by the bacteria Shigella dysenteria while Shiga-like toxin (Stx2) is a verotoxin produced by certain strains of Escherichia coli . Stx2 and stx2B encodes the two subunits of the holotoxin that work cooperatively to induce apoptosis in human endothelial cells. Stx2 is associated with hemolytic uremic syndrome (HUS), which causes significant morbidity and mortality in infected humans. Currently, there are no vaccines to protect against Stx or HUS. Stx2B is responsible for eliciting an immune response in humans, but by itself is not toxic. The goal of the project is to introduce stx2B into a novel FliC cloning platform (R2-HTI)*. This will allow the immunogenic protein encoded by stx2b to be expressed as a fusion protein with FliC resulting in an enhanced immune response.